Cutia Therapeutics (HKG:2487)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.750
-0.090 (-1.86%)
Apr 17, 2026, 3:41 PM HKT
Market Cap1.73B -9.7%
Revenue (ttm)374.07M +20.2%
Net Income-378.57M
EPS-1.14
Shares Out363.37M
PE Ration/a
Forward PE138.04
Dividendn/a
Ex-Dividend Daten/a
Volume36,200
Average Volume225,260
Open4.900
Previous Close4.840
Day's Range4.700 - 4.920
52-Week Range4.240 - 12.840
Beta0.53
RSI51.00
Earnings DateMar 24, 2026

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment;... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 304
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2487
Full Company Profile

Financial Performance

In 2025, Cutia Therapeutics's revenue was 336.15 million, an increase of 20.22% compared to the previous year's 279.62 million. Losses were -340.19 million, -21.58% less than in 2024.

Financial numbers in CNY Financial Statements